The World Health Organization (WHO) has recently reported that the global tuberculosis (TB) epidemic is larger than previously projected, with an estimated 10.4 million new (incident) cases occurring in 2015 (¹). It has thus become clear that the WHO End TB Strategy targets of a 90% reduction in TB incidence and a 95% reduction in TB deaths by 2035 can be achieved only by combining the effective detection and treatment of active TB with measures to prevent new infection with Mycobacterium tuberculosis and to eradicate existing latent TB infections (LTBI) (^{1 – 6}). Recent estimates indicate that approximately 1.7 billion people, nearly one‐quarter of the world's population, are latently infected with Mycobacterium tuberculosis and are at risk of progression to active TB without treatment (⁷). Moreover, an estimated 11% of those are likely infected with an isoniazid‐resistant strain. With ongoing transmission of M. tuberculosis and a high rate of reactivation from LTBI to active TB, a heightened global commitment to the identification and treatment of infected persons is thus critical for achievement of TB elimination (^{1 – 6 , 8 – 10}).